Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.74 |
| ▸ | DDR1 | Q08345 | 8/20 | 0.58 |
| ▸ | BCR | P11274 | 6/20 | 0.56 |
| ▸ | DDR2 | Q16832 | 6/20 | 0.56 |
| ▸ | KIT | P10721 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610957 | 0.92 | DDR1 (0.65) | ABL1DDR1BCRDDR2KIT | |
| SCHEMBL9610923 | 0.89 | NR2E1 (0.64) | ABL1DDR1BCRDDR2KIT | |
| SCHEMBL10266411 | 0.88 | ABL1 (0.74) | ABL1BCR | |
| SCHEMBL9611040 | 0.86 | ABL1 (0.75) | ABL1DDR1BCRDDR2KIT | |
| SCHEMBL9611146 | 0.86 | ABL1 (0.57) | ABL1DDR1BCRDDR2KIT | |
| SCHEMBL9610998 | 0.85 | DDR1 (0.56) | ABL1DDR1BCRDDR2KIT | |
| SCHEMBL588662 | 0.85 | ABL1 (1.00) | ABL1DDR1DDR2 | |
| SCHEMBL28778717 | 0.84 | ABL1 (0.69) | ABL1BCRKIT | |
| SCHEMBL9610798 | 0.83 | ABL1 (0.59) | ABL1DDR1BCRDDR2KIT | |
| SCHEMBL13813436 | 0.83 | ABL1 (0.55) | ABL1DDR1BCRDDR2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013162727-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885DDR1 4853/4885BCR 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.